KITS EYECARE LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.91 CAD | +4.23% |
|
-3.11% | -5.29% |
| Apr. 16 | KITS Eyecare Ltd. Announces Executive Appointments | CI |
| Apr. 10 | Kits Eyecare Announces Sabrina Liak Will Transition to Senior Advisor Role and Continue as Board Member | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 90.31 | 83.85 | 196 | 185.8 | - | - |
| Enterprise Value (EV) 1 | 92.74 | 78.2 | 189.7 | 174.9 | 167.2 | 185.8 |
| P/E ratio | -5.92 x | - | -89.1 x | -591 x | 59.1 x | - |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.1 x | 0.91 x | 1.63 x | 1.3 x | 1.13 x | - |
| EV / Revenue | 1.13 x | 0.85 x | 1.57 x | 1.22 x | 1.02 x | - |
| EV / EBITDA | -11.6 x | -42.8 x | 83.1 x | 38.3 x | 20.9 x | - |
| EV / FCF | -4.02 x | 17.7 x | 103 x | 21.6 x | 24.3 x | 19.8 x |
| FCF Yield | -24.9% | 5.65% | 0.97% | 4.63% | 4.11% | 5.04% |
| Price to Book | 1.65 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 31,141 | 31,287 | 31,411 | 31,440 | - | - |
| Reference price 2 | 2.900 | 2.680 | 6.240 | 5.910 | 5.910 | 5.910 |
| Announcement Date | 3/9/22 | 3/9/23 | 3/6/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 75.22 | 82.4 | 91.64 | 120.5 | 143.4 | 164.2 | - |
| EBITDA 1 | 3.548 | -8.004 | -1.828 | 2.284 | 4.564 | 7.984 | - |
| EBIT 1 | 0.122 | -17.04 | -4.352 | -2.382 | 0.3745 | 4.121 | - |
| Operating Margin | 0.16% | -20.68% | -4.75% | -1.98% | 0.26% | 2.51% | - |
| Earnings before Tax (EBT) 1 | -7.088 | -18.84 | - | - | -0.3 | 4.6 | - |
| Net income 1 | -6.583 | -14.62 | - | -2.215 | -0.2 | 3.3 | - |
| Net margin | -8.75% | -17.74% | - | -1.84% | -0.14% | 2.01% | - |
| EPS 2 | -0.7200 | -0.4900 | - | -0.0700 | -0.0100 | 0.1000 | - |
| Free Cash Flow 1 | 3.957 | -23.09 | 4.419 | 1.842 | 8.1 | 6.879 | 9.364 |
| FCF margin | 5.26% | -28.03% | 4.82% | 1.53% | 5.65% | 4.19% | - |
| FCF Conversion (EBITDA) | 111.53% | - | - | 80.65% | 177.47% | 86.16% | - |
| FCF Conversion (Net income) | - | - | - | - | - | 208.45% | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/15/21 | 3/9/22 | 3/9/23 | 3/6/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.03 | 20.27 | 20.05 | 21.77 | 23.58 | 26.24 | 27.67 | 30.03 | 31.15 | 31.66 | 34.29 | 34.96 | 36.32 | 36.56 |
| EBITDA 1 | -0.974 | -1.177 | - | -0.556 | -0.795 | 0.441 | 0.304 | 0.513 | 0.605 | 0.862 | 0.567 | 0.9945 | 1.209 | 1.358 |
| EBIT 1 | -2.414 | -3.212 | -1.769 | -0.722 | 0.166 | -1.222 | -0.913 | -1.224 | 0.67 | -0.915 | -0.6 | - | 0.3 | 0.3 |
| Operating Margin | -12.05% | -15.85% | -8.82% | -3.32% | 0.7% | -4.66% | -3.3% | -4.08% | 2.15% | -2.89% | -1.75% | - | 0.83% | 0.82% |
| Earnings before Tax (EBT) 1 | -2.786 | -3.612 | - | - | - | - | -1.294 | -1.45 | 0.552 | -0.699 | -0.7 | -0.1 | 0.2 | 0.3 |
| Net income 1 | -2.137 | -4.054 | - | - | - | - | -1.02 | -1.184 | 0.48 | -0.491 | -0.5 | -0.1 | 0.2 | 0.2 |
| Net margin | -10.67% | -20% | - | - | - | - | -3.69% | -3.94% | 1.54% | -1.55% | -1.46% | -0.29% | 0.55% | 0.55% |
| EPS 2 | -0.0700 | -0.1300 | - | - | - | - | -0.0300 | -0.0400 | 0.0100 | -0.0200 | -0.0200 | - | - | 0.0100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/9/22 | 5/11/22 | 8/11/22 | 11/9/22 | 3/9/23 | 5/10/23 | 8/9/23 | 11/8/23 | 3/6/24 | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 2.44 | - | - | - | - | - |
| Net Cash position 1 | - | - | 5.65 | 6.32 | 10.9 | 18.6 | - |
| Leverage (Debt/EBITDA) | - | -0.3042 x | - | - | - | - | - |
| Free Cash Flow 1 | 3.96 | -23.1 | 4.42 | 1.84 | 8.1 | 6.88 | 9.36 |
| ROE (net income / shareholders' equity) | - | -53.9% | -8.39% | -4.21% | -3.1% | 0.2% | - |
| ROA (Net income/ Total Assets) | -12% | -20.1% | -4.93% | -2.44% | -1.8% | 0.1% | - |
| Assets 1 | 54.66 | 72.8 | - | 90.75 | 11.11 | 3,300 | - |
| Book Value Per Share | -0.0600 | 1.760 | - | - | - | - | - |
| Cash Flow per Share 2 | 0.4500 | -0.6500 | 0.1500 | 0.0800 | 0.1800 | 0.2300 | - |
| Capex 1 | 0.23 | 3.63 | 0.26 | 0.56 | 0.6 | 0.61 | 0.52 |
| Capex / Sales | 0.3% | 4.41% | 0.28% | 0.47% | 0.42% | 0.37% | - |
| Announcement Date | 3/15/21 | 3/9/22 | 3/9/23 | 3/6/24 | - | - | - |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.91
CAD
Average target price
9.292
CAD
Spread / Average Target
+57.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.29% | 136M | |
| -11.39% | 3.86B | |
| -14.57% | 1.4B | |
| +15.07% | 713M | |
| -30.64% | 483M | |
| -23.65% | 364M | |
| +21.86% | 188M | |
| -23.15% | 128M | |
| -4.91% | 109M | |
| +0.33% | 92.65M |
- Stock Market
- Equities
- KITS Stock
- Financials Kits Eyecare Ltd.
